Compare Biogen Inc (BIIB) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Tesla, Inc. — how do they compare? Biogen Inc trades at $194.08 (market cap $28.34B), while Tesla, Inc. trades at $396.17 (market cap $1.49T). The key difference: Tesla, Inc. is far larger — about 52.6× Biogen Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals.
| BIIB | TSLA | |
|---|---|---|
Market Cap | $28.34B | $1.49T |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $489.88 |
52-Week Low | $122.68 | $302.63 |
Enterprise Value | $30.62B | $1.46T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Tesla (TSLA) trades at $396.87, up 0.53% with mixed technical signals showing bearish moving averages but neutral oscillators. The company faces valuation challenges with a P/E ratio of 363.47 and declining profit margins, though recent earnings beat expectations in Q1 2026. Positive developments include regulatory approval for self-driving software in Europe and strong growth in German registrations.
Tesla's outlook balances innovation potential against execution risks. The stock offers exposure to autonomous driving leadership and energy growth, but faces intense EV competition and margin pressure. Analyst consensus price target of $409.26 suggests modest upside, though institutional sentiment remains divided with 39.5% buy ratings versus 18.5% sell recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
